Inhibitory effect of 2'-o-methoxyethyl-modified antisense oligonucleotides targeting vascular endothelial growth factor A on SKOV3 human ovarian cancer cells.
- Author:
Yi-Bing FU
1
;
Ze-Qing WEN
;
Xing-Bo ZHAO
;
Lei YAN
;
Chun-Hua ZHANG
;
Fei WANG
Author Information
- Publication Type:Journal Article
- MeSH: Blotting, Western; Cell Line, Tumor; Cell Movement; drug effects; Female; Humans; Oligonucleotides, Antisense; pharmacology; Ovarian Neoplasms; metabolism; Vascular Endothelial Growth Factor A; antagonists & inhibitors; metabolism
- From: Chinese Medical Journal 2011;124(10):1573-1575
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDOvarian cancers are often at an advanced stage at diagnosis because early detection is difficult. The poor prognosis of ovarian cancers highlights the crucial need to develop better therapeutic agents and strategies. The objective of this study was to investigate the inhibitory effects of a new modified antisense oligonucleotides targeting vascular endothelial growth factor A (VEGF-A) in SKOV3 ovarian cancer cells.
METHODSAntisense oligonucleotides targeting VEGF-A was designed, synthesized and transfected into SKOV3 ovarian cancer cells. Western blotting and real-time RT-PCR were used to analyze the inhibitory effects of antisense oligonucleotides on VEGF-A protein and mRNA expression. Transwell matrix assay was used to detect cell migration inhibition.
RESULTSThe antisense oligonucleotides targeting VEGF-A significantly decreased VEGF-A protein and mRNA expression and inhibited cell migration in SKOV3 ovarian cancer cells.
CONCLUSIONSThis new modified antisense oligonucleotides targeting VEGF-A can decrease VEGF-A expression and inhibit cell migration in SKOV3 ovarian cancer cells. This new oligonucleotides may be a promising therapeutic agent for ovarian cancers.
